Portland
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
179- Dermatology
- 123
- Plastic Surgery
- 56
Vendor qualification for medspas and aesthetic practices
Medspas operate under physician supervision, and that supervising physician's practice is usually the one that qualifies a new biologics vendor. A standard review covers whether the distributor sells only to licensed accounts, whether pricing is published anywhere (it should not be), and whether registration and licensure documentation is available for the practice to verify directly rather than take on faith.
Because Wharton's jelly products are not stem cell therapies and commercial cord-tissue allografts are not documented to contain viable, functional stem cells, practices evaluating this category should ask a prospective supplier for its processing description and lot documentation rather than rely on category-level marketing language.
What to request before stocking a lot
A short documentation checklist covers the material facts a practice needs on file for any lot it stocks, regardless of format.
- Certificate of analysis for the specific lot
- Donor eligibility summary
- Lot release record
- For exosome products, supplier characterization data (such as particle concentration method and marker panel) on request
Receiving and storing shipments
Cryopreserved Wharton's jelly formats arrive overnight on dry ice in validated containers and are stored at -80 degrees C until use; lyophilized Wharton's jelly and exosome formats ship shelf-stable and are stored and reconstituted per the insert included with the lot. Front-desk or clinical intake staff at a Portland practice should log each shipment's lot identifier against the packing slip before it enters inventory.
Confirm your regulatory posture directly
Dermatology and plastic surgery practices should route questions about how a specific Wharton's jelly or exosome product fits their regulatory framework to their own counsel and, where relevant, the Oregon Medical Board, rather than to a product distributor. Precision Biologics supports the procurement side of that process: NPI verification, documentation requests, and physician-level calls about product documentation.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a medspa order directly, or does the supervising physician need to be on the account?+
Accounts are opened for licensed providers and verified through an NPI number, which typically means the supervising physician's credentials are part of account setup.
Are Wharton's jelly products sold as stem cell therapies?+
No. Precision Biologics does not market these as stem cell therapies, and commercial cord-tissue allografts are not documented to contain viable, functional stem cells.
How do we verify a lot before using it in the practice?+
Request the certificate of analysis, donor eligibility summary, and lot release record for that specific lot, and confirm the lot identifier on the shipment matches your paperwork.